No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LFVN240719C7500
- 0.05
- 0.000.00%
15min DelayClose Jul 19 15:55 ET
0.10High0.05Low
0.10Open0.05Pre Close2 Volume50 Open Interest7.50Strike Price15.00Turnover1123.97%IV14.22%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1401Delta0.3028Gamma132.20Leverage Ratio-2.2703Theta0.0000Rho18.52Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
News
LifeVantage Corporation's (NASDAQ:LFVN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
FDA Revokes Use of Brominated Vegetable Oil in Food
The Food and Drug Administration no longer allows the use of brominated vegetable oil as a food additive, finalizing a move the agency had signaled in November.
Lifevantage(LFVN.US) Director Buys US$3,609.86 in Common Stock
$Lifevantage(LFVN.US)$ Director Lewis Darwin purchased 489 shares of common stock on Jun 14, 2024 at an average price of $7.3821 for a total value of $3,609.86.Source: Announcement What is statement o
LifeVantage (NASDAQ:LFVN) May Have Issues Allocating Its Capital
Four Days Left Until LifeVantage Corporation (NASDAQ:LFVN) Trades Ex-Dividend
LifeVantage To Participate in Upcoming Investor Conferences
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellu
Comments
Raymond Greer's appointment is viewed as a way to ensure robust leadership and continuity, owing to his deep knowledge of the business and lengthy industry experience. The maneuver is deemed auspicious given LifeVantage's significant momentum.
Press Release: LifeVantage Appoints Raymond Greer as Chairman of the Board of DirectorsLifeVantage's dividend reliability is questionable due to continuous EPS decline, posing potential risk to long-term investors.
Management is confident in executing their LV360 strategy, delivering growth and value for stockholders, acknowledging persistent work ahead. Investors' support, both large institutional and smaller individual, was appreciated.
The CEO's inflated compensation doesn't match the company's poor performance. Shareholders may question the management at the AGM, as rising CEO pay contrasts with falling EPS and shareholder losses.
$Lifevantage (LFVN.US)$ turn around not over yet, the little drama is almost over 6th November.
1
Read more